Jun 62026 Daraxonrasib Drug Doubles Pancreatic Cancer Survival Rate in Phase 3 Trial An inhibitor targeting the RAS pathway, which is commonly mutated in cancer, could change the way doctors treat pancreatic and other cancers.
